Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis

Lu Wang, Wanyue Sang, Yi Jian, Xiaoxue Zhang, Yafan Han, Feifei Wang, Liang Wang, Suxia Yang, Subinuer Wubulikasimu, Li Yang, Huaxin Sun, Yaodong LiFrontiers in Cardiovascular Medicine 2023 · DOI

Abstract

This meta-analysis evaluates the safety and efficacy of Novel Oral Anticoagulants (NOACs) versus Vitamin K Antagonists (VKAs) in patients with atrial fibrillation (AF) following Transcatheter Aortic Valve Replacement (TAVR). Analysis of 13 studies involving over 30,000 patients indicates that NOACs significantly reduce the incidence of major bleeding and all-cause mortality compared to VKAs, while maintaining comparable stroke prevention.

Introduction

Transcatheter Aortic Valve Replacement (TAVR) has become a standard, less invasive treatment for severe aortic stenosis. However, many TAVR patients also suffer from atrial fibrillation (AF)—either pre-existing or developed shortly after the procedure. AF significantly increases the risk of stroke, necessitating anticoagulant therapy.

Historically, Vitamin K Antagonists (VKAs) like warfarin were the gold standard. While Novel Oral Anticoagulants (NOACs) like apixaban and rivaroxaban have proven superior in general AF populations, their efficacy and safety specifically in the high-risk post-TAVR population remained controversial. This paper performs a systematic meta-analysis to provide a clearer evidence-based recommendation for clinicians balancing ischemic stroke prevention against life-threatening bleeding complications.

Methods

The researchers conducted a systematic review following PRISMA guidelines, searching major databases (PubMed, EMBASE, Medline, and Cochrane) through January 2023.

Figure 1: Flow diagram showing the literature search and study selection process.

They identified 13 relevant studies: 3 Randomized Controlled Trials (RCTs) and 10 observational studies, encompassing a total of 30,388 post-TAVR patients with AF. The team used a random-effects model to calculate Risk Ratios (RR) and 95% Confidence Intervals (CI), alongside the Number Needed to Treat (NNT) to provide practical clinical context.

Key Insights and Results

The analysis revealed that patients in the NOAC and VKA groups had similar baseline risk profiles for stroke, as evidenced by comparable CHA2DS2-VASc scores across the cohorts.

Figure A: Comparison of baseline CHA2DS2-VASc scores between NOAC and VKA groups.

Despite these similar baseline risks, the outcomes significantly favored NOACs in several key metrics:

  • The Safety Advantage: NOACs were associated with a significantly lower risk of major bleeding (11.29% vs. 13.89%; RR 0.82, p < 0.00001). The NNT to prevent one major bleeding event was 38.
  • Mortality Benefit: Lowering the risk of major bleeding translated into a lower all-cause mortality rate (14.18% vs. 17.61%; RR 0.83, p < 0.00001). The NNT for all-cause mortality was 29.
  • Stroke Parity: Despite the lower bleeding risk, NOACs did not sacrifice efficacy in stroke prevention. The rates of stroke were statistically indistinguishable between the two groups (2.99% for NOAC vs. 2.83% for VKA; RR 1.05, p = 0.48).

Discussion and Limitations

The findings suggest that NOACs offer a superior safety profile for the elderly and often frail post-TAVR population. However, several limitations must be considered. Ten of the thirteen studies were observational, which can be influenced by "prescriber bias" where healthier patients might have been more likely to receive NOACs. Additionally, there was significant statistical heterogeneity (I² up to 82% for mortality), likely due to differences in study design and patient demographics.

While the study looked at NOACs as a class, it noted that rivaroxaban was the most used, but apixaban showed slightly better adverse event profiles in some subgroups. Future high-quality RCTs are needed to harmonize dosing strategies, especially concerning the combination of NOACs with antiplatelet therapy.

Conclusion

For post-TAVR patients with AF, NOACs appear to be a safer and more effective alternative to VKAs, significantly reducing major bleeding and mortality without compromising stroke protection.

Summary updated

Abstract

Taken together, our data indicated that the usage of NOACs reduced the incidence of major bleeding and all-cause mortality compared to VKAs in post-TAVR patients with AF.
BibTeX
@inproceedings{wang2023post,
  author = {Lu Wang and Wanyue Sang and Yi Jian and Xiaoxue Zhang and Yafan Han and Feifei Wang and Liang Wang and Suxia Yang and Subinuer Wubulikasimu and Li Yang and Huaxin Sun and Yaodong Li},
  title = {{Post-TAVR patients with atrial fibrillation: are NOACs better than VKAs?—A meta-analysis}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2023},
  doi = {10.3389/fcvm.2023.1175215},
}
Figure